[FCSC] Fibrocell Science Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.69 Change: -0.06 (-8%)
Ext. hours: Change: 0 (0%)

chart FCSC

Refresh chart

Strongest Trends Summary For FCSC

FCSC is in the medium-term down -21% below S&P in 4 months. In the long-term down -50% below S&P in 2 years and down -100% below S&P in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing various treatments for skin diseases and conditions with unmet medical needs. The company, through its proprietary autologous fibroblast technology, Fibrocell, develops biologic solutions and medical applications of azficel-T for restrictive burn scarring and vocal cord scarring conditions; and biologic products for patients with rare genetic skin and tissue disorders. It has collaboration agreements with Intrexon Corporation for using genetically-modified fibroblasts for treating rare and serious skin, and connective tissue diseases; and University of California, Los Angeles to focus on skin-derived stem cells and other ways to convert skin cells to other cell types. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 234.48% Sales Growth - Q/Q246.43% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-48.97% ROE-90.53% ROI
Current Ratio5.79 Quick Ratio5.7 Long Term Debt/Equity Debt Ratio0.27
Gross Margin-407.93% Operating Margin-7871.34% Net Profit Margin-6148.17% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities150 K Cash From Investing Activities-110 K Cash From Operating Activities-4.24 M Gross Profit50 K
Net Profit-8.53 M Operating Profit-6.86 M Total Assets41.18 M Total Current Assets34.93 M
Total Current Liabilities6.03 M Total Debt Total Liabilities18.9 M Total Revenue190 K
Technical Data
High 52 week4.8 Low 52 week1.5 Last close1.99 Last change3.92%
RSI28.1 Average true range0.13 Beta0.53 Volume94.25 K
Simple moving average 20 days-9.64% Simple moving average 50 days-6.39% Simple moving average 200 days-2.27%
Performance Data
Performance Week-6.57% Performance Month-11.95% Performance Quart-1.97% Performance Half0%
Performance Year-33.49% Performance Year-to-date32.67% Volatility daily4.16% Volatility weekly9.31%
Volatility monthly19.07% Volatility yearly66.06% Relative Volume107.4% Average Volume978.79 K
New High New Low

News

2019-08-15 07:45:19 | The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

2019-08-14 16:45:00 | Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

2019-07-11 09:44:37 | How Fibrocell Science, Inc. NASDAQ:FCSC Can Impact Your Portfolio Volatility

2019-06-13 09:50:01 | Savara Plunges on Failure of Late-Stage Study on Molgradex

2019-05-30 08:44:12 | Fibrocell Up on FDA Designation for Gene Therapy Candidate

2019-05-30 08:00:00 | Fibrocell to Present at BIO International Convention 2019

2019-05-29 09:30:01 | Is Fibrocell Science FCSC Stock Outpacing Its Medical Peers This Year?

2019-05-29 08:00:00 | Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB

2019-05-16 10:03:02 | The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business

2019-05-15 09:34:01 | Fibrocell FCSC Miss Estimates for Earnings & Revenues in Q1

2019-05-15 08:11:12 | Small Business Optimism Hits 4-Month High in April: 5 Picks

2019-05-15 07:30:00 | Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights

2019-05-13 09:30:01 | Is Fibrocell Science FCSC Outperforming Other Medical Stocks This Year?

2019-05-13 08:44:12 | Blueprint Medicines BPMC Q1 Earnings & Sales Lag Estimates

2019-05-10 15:27:07 | Global Blood GBT Reports Narrower-Than-Expected Loss in Q1

2019-05-10 14:54:06 | Agenus AGEN Q1 Earnings Beat Estimates, Revenues Miss

2019-05-10 10:11:02 | Spectrum Pharma SPPI Q1 Earnings Lag Estimates, Revenues Nil

2019-05-10 10:00:02 | Puma Biotech PBYI Q1 Earnings Top, Nerlynx Disappoints

2019-05-10 08:34:12 | Intrexon XON Reports In-Line Q1 Loss, Misses on Revenues

2019-05-09 18:17:10 | Horizon Therapeutics' HZNP Q1 Earnings Beat Estimates

2019-05-09 15:21:07 | Amicus' FOLD Earnings & Revenues Miss Estimates in Q1

2019-05-09 15:03:07 | IVERIC bio's ISEE Q1 Loss Narrows, Gene Therapy in Focus

2019-05-09 11:05:03 | Sarepta SRPT Q1 Earnings Top Estimates, Exondys 51 Sales Up

2019-05-09 09:03:01 | Arena Pharmaceuticals' ARNA Loss Widens in Q1 But Stock Up

2019-05-09 08:00:00 | Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

2019-05-09 06:57:10 | AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

2019-05-07 13:51:05 | Mylan's MYL Q1 Earnings Beat Estimates, Revenues Miss

2019-05-07 08:56:12 | Ultragenyx RARE Reports Wider-Than-Expected Loss in Q1

2019-04-30 17:50:09 | Fibrocell Science FCSC Flat As Market Gains: What You Should Know

2019-04-25 09:30:01 | Is Fibrocell Science FCSC Stock Outpacing Its Medical Peers This Year?

2019-04-17 09:14:00 | These 2 Biotech Stocks Are No Longer 'Off the Radar'

2019-04-17 07:48:11 | Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

2019-04-16 19:26:11 | ProQR Initiates Dosing in Phase II/III Eye Disorder Study

2019-04-16 10:59:02 | Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises

2019-04-15 13:22:55 | Fibrocell signs $135M deal to advance therapy for 'butterfly children'

2019-04-15 06:30:00 | Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

2019-04-03 08:00:00 | Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors

2019-03-27 07:30:00 | Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007

2019-03-20 08:00:00 | Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019

2019-02-06 08:00:00 | Fibrocell to Present at 21st Annual BIO CEO & Investor Conference

2019-01-16 08:00:00 | Fibrocell to Present at Phacilitate Leaders World 2019

2018-12-11 08:00:00 | Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation

2018-12-04 14:16:31 | What Kind Of Shareholders Own Fibrocell Science Inc NASDAQ:FCSC?

2018-11-19 08:30:00 | Market Trends Toward New Normal in Fibrocell Science, Sears Hometown and Outlet Stores, Apellis Pharmaceuticals, Sigma Labs, Highpower International, and Nicholas Financial — Emerging Consolidated Expectations, Analyst Ratings

2018-11-13 08:00:00 | Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights

2018-11-09 14:08:07 | Intrexon XON Reports Narrower-Than-Expected Loss in Q3

2018-11-08 08:00:00 | Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights

2018-10-25 08:00:00 | Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007

2018-09-26 08:00:00 | Fibrocell to Present at Upcoming Industry and Investor Conferences

2018-09-25 08:00:00 | Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa